01.002 RWE TNT May 2022 D 19-05-2022

Real-world evidence (RWE) shows good acceptance of rituximab biosimilar in non-Hodgkin lymphoma (NHL)

  • The retrospective study, published in Future Oncology, is one of the first to investigate the acceptance of rituximab biosimilars in the United States in an oncology setting and the first study to examine real-world data for rituximab-pvvr [biosimilar]
  • Although rituximab-pvvr was only recently introduced to market, the preliminary results suggest that this medication is being accepted in US oncology practice and is being used in a manner consistent with clinical guidelines in which the use of rituximab is recommended as part of a combination regimen with chemotherapy, targeted therapy, or immunotherapy
  • Oncology biosimilars have the potential to improve patient access to treatments and reduce biologics spending by $44 billion over a 10-year period

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at